CIK 0001650664
- Non-accelerated filer
- Smaller reporting company
Editas Medicine, Inc.
Sign in to watch- Ticker
- EDIT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464097528
- Phone
- +1 617-401-9000
- Business address
- 11 HURLEY ST., CAMBRIDGE, MA, 02141
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $89,088
- in 5 filings, $89K under 10b5-1 plans
Net −$89,088. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-02-13 | Shearman Mark S EVP, CHIEF SCIENTIFIC OFFICER | Sale | −2,790 | $9.67 | $27K | 65,559 |
| 2022-06-15 | Shearman Mark S EVP, CHIEF SCIENTIFIC OFFICER | Sale | −5,145 | $10.06 | $52K | 68,349 |
| 2022-02-10 | Shearman Mark S EVP, CHIEF SCIENTIFIC OFFICER | Grant or award | +31,709 | 73,494 | ||
| 2022-02-10 | Shearman Mark S EVP, CHIEF SCIENTIFIC OFFICER | Grant or award · Stock Option (right to buy) | +93,398 | 93,398 | ||
| 2021-12-22 | Shearman Mark S EVP, Chief Scientific Officer | Grant or award | +9,084 | 41,785 | ||
| 2021-06-14 | Shearman Mark S EVP, Chief Scientific Officer | Grant or award | +32,701 | 32,701 | ||
| 2021-06-14 | Shearman Mark S EVP, Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +52,718 | 52,718 |
Page 1 of 1 · 7 trades